Elanco Animal Health Incorporated (ELAN) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2025-03-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2025-03-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2025-03-31..
Borrowing debt
Overview →Financial period ending 2025-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2025-03-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2025-03-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2025-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 44.00M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 4.35B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 12.94B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | (m) | (m) | $44.00M | $4.35B | (m) | (m) | $12.94B | (m) |
| 2024-12-31 | (m) | (m) | $44.00M | $4.28B | (m) | (m) | $12.61B | (m) |
| 2024-09-30 | (m) | (m) | $44.00M | $4.31B | (m) | (m) | $13.28B | (m) |
| 2024-06-30 | (m) | (m) | $213.00M | $5.46B | (m) | (m) | $13.76B | (m) |
| 2024-03-31 | (m) | (m) | $38.00M | $5.73B | (m) | (m) | $14.02B | (m) |
| 2023-12-31 | (m) | (m) | $38.00M | $5.74B | (m) | (m) | $14.36B | (m) |
| 2023-09-30 | (m) | (m) | $39.00M | $5.87B | (m) | (m) | $14.34B | (m) |
| 2023-06-30 | (m) | (m) | $39.00M | $6.02B | (m) | (m) | $15.80B | (m) |
| 2023-03-31 | (m) | (m) | $381.00M | $5.64B | (m) | (m) | $15.77B | (m) |
| 2022-12-31 | (m) | (m) | $388.00M | $5.45B | (m) | (m) | $15.49B | (m) |
| 2022-09-30 | (m) | (m) | $394.00M | $5.51B | (m) | (m) | $14.95B | (m) |
| 2022-06-30 | (m) | (m) | $56.00M | $6.01B | (m) | (m) | $15.60B | (m) |
| 2022-03-31 | (m) | (m) | $61.00M | $6.07B | (m) | (m) | $16.25B | (m) |
| 2021-12-31 | (m) | (m) | $294.00M | $6.03B | (m) | (m) | $16.48B | (m) |
| 2021-09-30 | (m) | (m) | $61.00M | $6.27B | (m) | (m) | $16.57B | (m) |
| 2021-06-30 | (m) | (m) | $555.00M | $5.54B | (m) | (m) | $16.83B | (m) |
| 2021-03-31 | (m) | (m) | $605.00M | $5.56B | (m) | (m) | $16.99B | (m) |
| 2020-12-31 | (m) | (m) | $554.50M | $5.57B | (m) | (m) | $17.69B | (m) |
| 2020-09-30 | (m) | (m) | $553.60M | $5.59B | (m) | (m) | $17.24B | (m) |
| 2020-06-30 | (m) | (m) | $25.90M | $2.03B | (m) | (m) | $9.88B | (m) |
| 2020-03-31 | (m) | (m) | $26.00M | $2.04B | (m) | (m) | $9.73B | (m) |
| 2019-12-31 | (m) | (m) | $24.50M | $2.33B | (m) | (m) | $8.99B | (m) |
| 2019-09-30 | (m) | (m) | $24.50M | $2.34B | (m) | (m) | $8.82B | (m) |
| 2019-06-30 | (m) | (m) | $27.10M | $2.38B | (m) | (m) | $8.86B | (m) |
| 2019-03-31 | (m) | (m) | $29.00M | $2.44B | (m) | (m) | $8.75B | (m) |
| 2018-12-31 | (m) | (m) | $29.00M | $2.44B | (m) | (m) | $8.96B | (m) |
| 2018-09-30 | (m) | (m) | $0.00 | $2.48B | (m) | (m) | $9.21B | (m) |
| 2017-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | $8.94B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |